Drug intelligence / Profile preview

ETH-154

Development stage: Preclinical
Lead developer: Shengke Pharmaceuticals Ltd.
Modality: Small Molecules

Overview

ETH-154 is a small molecule inhibitor of human cyclin-dependent kinases (HuCDKs) currently in preclinical development by Shengeke Pharmaceuticals. The drug is specifically being investigated for the treatment of gastric cancer, including advanced gastric cancer (AGC) and non-HER2 gastric cancer (NHGCC). By targeting CDKs, which are critical regulators of the cell cycle, ETH-154 aims to arrest the uncontrolled proliferation of malignant cells in solid tumors. Shengeke Pharmaceuticals is focusing on this candidate as part of its oncology pipeline targeting novel small molecule mechanisms for difficult-to-treat cancers.

Targets

CDK (CDK family)

Beyond the preview

Go deeper on ETH-154.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETH-154.

Explore the full profile